Unmet need
18%
On advanced therapy, not in remission
9%
Needed steroids in the first year of advanced therapy
9%
On a 3rd advanced therapy or later
10%
Primary non-response to an advanced therapy
The answers are already in the chart. CleverConsult makes them visible.
Trusted by specialists at
How CleverConsult works
Two tools built from the chart you already have
CleverConsult ingests the entire medical record from all your IBD patients and surfaces the details that matter to you and your patients.
01 · IBD Profile
One patient's story at the point of care
The patient's entire IBD history in one continuously updated summary: diagnosis, every treatment and response, labs, drug levels, endoscopy, imaging and surgeries. Every fact links back to its source document.
See a demo patient below 02 · IBD Dashboard Coming soonYour entire IBD practice in one view
Every IBD patient you follow, so you can find trends and gaps in care, patients lost to follow-up and patients who may fit a clinical trial.
See the dashboard01 · IBD Profile
For the patient in the room
The IBD Profile assembles every step of the patient's IBD journey and traces each fact back to its source document for verification.
Instantly see every endoscopy, pathology, imaging, TDM, fecal cal.
Have your patient's full history at your fingertips.
Verify each fact with citations.
Click the citation to open the source document it came from.
Effortless clinical trial screening.
Check your patient against actively recruiting clinical trials in your area.
Demo patients are synthetic. Every chart was de-identified.
Want the IBD Profile for your patients?
Tell us about your practice and we'll set it up for you.
02 · IBD Dashboard Coming soon
For your entire IBD practice
The IBD Dashboard displays a real-time view of your entire IBD practice.
See treatment journeys.
Track therapy duration, dose escalation, and discontinuation, with the documented reason for each change.
Ask any question.
Who on anti-TNF has had no TDM or fecal calprotectin in the past 12 months? Who with long-standing UC is due for surveillance colonoscopy?
Turn care gaps into call lists.
Find every patient overdue for a test or follow-up, and automatically task your admin to book it.
The full dashboard also covers care gaps, disease activity and remission, current therapy, steroid exposure and trial eligibility, and every view can be filtered by disease and drug.
Treatment sequencing
Where patients went after stopping an advanced therapy, by drug class.
| From ↓ To → | Anti-TNF | Anti-integrin | IL-12/23 inhibitor | IL-23 inhibitor | JAK inhibitor | S1P modulator |
|---|---|---|---|---|---|---|
| Anti-TNF | 24% | 17% | 19% | 24% | 16% | – |
| Anti-integrin | 38% | – | 16% | 23% | 22% | 1% |
| IL-12/23 | 28% | 24% | 1% | 32% | 14% | – |
| IL-23 | 31% | 19% | 4% | 15% | 31% | – |
| JAK | 29% | 21% | 4% | 35% | 10% | 2% |
Read across a row: of all switches away from that class, the share that went to each column. Lighter cells rest on fewer than 10 switches.
Persistence by drug class
Share of courses still on therapy at 12 months.
- Anti-TNF85%
- Anti-integrin75%
- IL-12/23 inhibitor89%
- IL-23 inhibitor91%
- JAK inhibitor83%
Persistence by therapy line
Share of courses still on therapy at 12 months.
- 1st line (no previous biologic)90%
- 2nd line or later81%
Want the IBD Dashboard for your practice?
Register your interest and we'll let you know as soon as it's live.
Clinical trial screening
Clinical trial recruitment, built into patient care
Every trial, checked automatically
Each patient is screened against every active trial's inclusion and exclusion criteria while the chart is reviewed. There is no separate chart review and nothing to set up. Only trials at your site or nearby sites are included.
Criterion by criterion
Open a trial to see which criteria the patient meets, which rule them out, and the chart evidence behind each one.
A person makes the call
Anything the chart cannot settle is flagged for review, so a coordinator confirms before the patient is approached.
Last run 2026-10-08 08:26
Needs review2
Study 1Show ▾Hide ▴
Meets: Documented diagnosis of Crohn's disease ≥3 months prior to screening
Ileocolonic Crohn's disease confirmed endoscopically and histologically (colonoscopy with biopsy, May 2016).
Meets: Age ≥18 years at screening
34-year-old; meets the age criterion.
Needs review: Moderately to severely active disease per a validated clinical disease activity index
No formal disease activity index documented. Clinic note 22 Sep 2026 reports 5–6 liquid stools/day and daily abdominal pain × 6 weeks, suggestive of moderate activity; index to be calculated at screening.
Meets: Endoscopic evidence of mucosal ulceration within 12 months of screening
Ileocolonoscopy 14 Jul 2026: SES-CD 9, with ulceration of the terminal ileum and ascending colon consistent with active ileocolonic disease.
Needs review: No fibrostenotic stricture anticipated to require surgical intervention
MR enterography 2 Aug 2026: 6 cm terminal ileal stricture with prestenotic dilatation. Clinical significance (obstructive symptoms) requires investigator review.
Meets: No live attenuated vaccine within 4 weeks of baseline
No immunizations documented since Oct 2025.
Meets: No malignancy within 5 years of screening
No history of malignancy documented.
Study 2Show ▾Hide ▴
Meets: Diagnosis of Crohn's disease confirmed by endoscopy and histopathology
Ileocolonic Crohn's disease confirmed endoscopically and histologically (colonoscopy with biopsy, May 2016).
Meets: Age ≥18 years at screening
34-year-old; meets the age criterion.
Meets: Inadequate response, loss of response or intolerance to ≥1 prior conventional or advanced therapy
Secondary loss of response to adalimumab (2023).
Needs review: Stable corticosteroid dose for ≥2 weeks prior to screening
Prednisone taper initiated 30 Sep 2026; dose not yet stable for the required interval.
Meets: No ostomy or functioning stoma
No stoma documented in the surgical history.
Meets: Adequate renal function (eGFR ≥60 mL/min/1.73 m²) within 6 months
eGFR 96 mL/min/1.73 m² (3 Sep 2026).
Ineligible3
Study 3Show ▾Hide ▴
Meets: Documented diagnosis of Crohn's disease ≥3 months prior to screening
Ileocolonic Crohn's disease confirmed endoscopically and histologically (colonoscopy with biopsy, May 2016).
Meets: Age 18–75 years at screening
34-year-old; meets the age criterion.
Meets: Endoscopic evidence of active mucosal inflammation
Ileocolonoscopy 14 Jul 2026: SES-CD 9, with ulceration of the terminal ileum and ascending colon consistent with active ileocolonic disease.
Does not meet: No infection requiring IV antimicrobial therapy within 30 days of baseline
Community-acquired pneumonia treated with IV ceftriaxone, 28 Sep to 3 Oct 2026.
Meets: Hemoglobin ≥90 g/L at screening
Hb 118 g/L (3 Sep 2026).
Meets: No ostomy or ileal pouch-anal anastomosis
No stoma or IPAA documented in the surgical history.
Study 4Show ▾Hide ▴
Does not meet: Diagnosis of ulcerative colitis confirmed by endoscopy and histopathology
Established diagnosis of Crohn's disease (ileocolonic, Montreal L3); no histologic or endoscopic evidence supporting ulcerative colitis.
Meets: Age ≥16 years at screening
34-year-old; meets the age criterion.
Meets: No Clostridioides difficile infection within 60 days of screening
C. difficile toxin/PCR negative (22 Sep 2026).
Meets: No prior colectomy or ostomy
Surgical history limited to ileocecal resection (2019).
Study 5Show ▾Hide ▴
Does not meet: Diagnosis of ulcerative colitis ≥3 months prior to screening
Established diagnosis of Crohn's disease (ileocolonic, Montreal L3); no histologic or endoscopic evidence supporting ulcerative colitis.
Meets: Age ≥18 years at screening
34-year-old; meets the age criterion.
Meets: Prior exposure to ≥1 advanced therapy (biologic or targeted small molecule)
Prior exposure to adalimumab (anti-TNF) and vedolizumab (anti-integrin).
Meets: No active or latent tuberculosis
Interferon-gamma release assay negative (Feb 2024).
Meets: No malignancy within 5 years of screening
No history of malignancy documented.
Why this matters
The answers are already in the chart
We know the guidelines. But the details that matter most are often buried in long charts, and patients who miss tests or appointments quietly fall behind. The published evidence shows what those gaps cost.
21%
of biologic-naïve UC patients who were overdue for follow-up had inflammation on fecal calprotectin while in clinical remission.
MacKay et al., Diseases, 2025. https://doi.org/10.3390/diseases14010002
69%
of IBD patients diagnosed with colorectal cancer had no colonoscopy in the prior 5 years.
Kim et al., Clinical Gastroenterology and Hepatology, 2022. https://doi.org/10.1016/j.cgh.2022.02.048
11% to 82%
Bone density screening rates in IBD patients before and after reminders, including an EMR prompt, made the indication visible in clinic.
Shah-Khan et al., BMJ Open Quality, 2019. https://doi.org/10.1136/bmjoq-2019-000624
Trusted by hundreds of specialists across Canada
Also included
Pre-visit charting and an AI scribe for clinic and procedure days
CleverConsult pre-drafts your note from the referral, recent visits, imaging and labs. Our GI-specific scribe completes it during the visit.
Smart document reviewer
Reads and extracts relevant data and drafts a clinical note into your customized template.
Intake forms
Patients complete a customized questionnaire and answers are seamlessly integrated into the clinical note.
Specialist scribe
With the clinical note 80% done, our specialized scribe will complete your clinical or procedure note effortlessly.
Security and integration
Built for Canadian health data
We comply with the federal and provincial health data regulations that apply to your practice, and CleverConsult works inside Accuro® through an API integration.
Privacy and Trust centre
SOC 2 Type II
Independently audited security controls.
- PHIPAOntario
- PIPEDACanada
- HIAAlberta
- HIPASaskatchewan
API integration with
Our Co-founder
What you need to know
Frequently asked questions
Does this work with my EMR?
Yes, if you use Accuro: CleverConsult works inside it through an API integration. With any other EMR, fax or upload the referral package and copy the note back into your EMR.
Is the IBD Dashboard available yet?
The IBD Dashboard is coming soon. The IBD Profile is available now.
Is this hard to implement?
No. Save your CleverConsult fax-to number in your EMR and start faxing us your referrals.
Is it PHIPA/PIPEDA compliant?
Yes. Legal and privacy are incredibly important to us. We're fully compliant with patient health information regulations and develop with security and privacy in mind.
Do I require consent from my patients to use CleverConsult?
No. CleverConsult is part of your toolset as the Health Information Custodian (HIC) and no consent is needed from patients to use it.
How do I get started?
Click "Try it free", select a time for a 15-minute onboarding meeting, and we'll see you on the virtual call at the time you selected.
Can I use templates from another scribe?
Yes. Copy and paste your templates into our template builder and you'll be set.
Do you offer a free trial?
Yes. Every account starts with a 14-day free trial, and no credit card is required.